Biofrontera Inc. (BFRIW) stock analysis
From the 10-K filed 2026-03-19
How it makes money
Dermatology offices pay for its products to treat skin lesions, with revenue driven by direct sales.
The Company sells a prescription drug and a specific light source to medical practitioners. This combination is used for photodynamic therapy (PDT), a process where a drug is applied to the skin and then activated by a light source to kill abnormal cells.
What protects it: the moat
Management claims that patent and trademark transfers strengthen its market position in the United States.
The Company acquired the U.S. rights to its primary products through a strategic transaction with its parent organization.
What growth costs
The Company invests in research and development to expand its product indications.
It focuses on label expansion, which involves seeking regulatory approval to use the drug for different skin conditions or types of lesions.
What could damage it
The entry of generic drugs could force the Company to lower prices and lose market share.
The entry of lower-cost, non-proprietary versions of its drug would directly reduce the Company's ability to command high prices.
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.